Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024)
Summit Therapeutics' (SMMT) quarterly Non-Current Debt came in at $100.0 million in Q1 2024, little changed YoY from $100.0 million in Q2 2023, and little changed on a QoQ basis from $100.0 million in Q4 2023.
Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 3 years of Non-Current Debt data on file, last reported at $100.0 million in Q1 2024.
- Quarterly Non-Current Debt changed 0.0% year-over-year to $100.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $100.0 million (changed 0.0% YoY) and the FY2023 annual result came in at $100.0 million, down 79.78% from the prior year.
- Non-Current Debt was little changed at $100.0 million in Q1 2024, from $100.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $494.5 million in Q4 2022 to a low of $25.1 million in Q1 2022.
- A 3-year average of $135.0 million and a median of $100.0 million in 2023 frame the typical range for Non-Current Debt.
- The widest YoY moves for Non-Current Debt: up 299.12% in 2023, down 79.78% in 2023.
- Tracing SMMT's Non-Current Debt over 3 years: stood at $494.5 million in 2022, then tumbled by 79.78% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024.
- The last three Non-Current Debt figures came in at $100.0 million (Q1 2024), $100.0 million (Q4 2023), and $100.0 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 100.00 Mn |
| Dec 31, 2023 | 100.00 Mn |
| Jun 30, 2023 | 100.00 Mn |
| Mar 31, 2023 | 100.00 Mn |
| Dec 31, 2022 | 494.54 Mn |
| Jun 30, 2022 | 25.31 Mn |
| Mar 31, 2022 | 25.06 Mn |